30 closest matches · ranked by relevance
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have · Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Primary: Number of Patients in Which the PI Observed a Notable Difference in the Number of Lesions — 4; 4 participants
Metastatic Colorectal Cancer · Skin Rash · Skin Toxicities
Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants
Colorectal Neoplasms · Metastases · Neoplasm
Primary: Percentage of Participants With an Overall Resonse — 8.2 percentage of participants
Skin Rash · Lung Cancer
Primary: Frequency of Participants Who Experienced Any Grade of Rash As Characterized By The Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0 — 44.5; 75.5 Percentage of…
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Rash
Primary: Overall Incidence of Rash — 84; 84; 82 percentage of participants — p=0.8769
Recurrent Skin Cancer · Squamous Cell Carcinoma of the Skin
Primary: Response Rate of Cetuximab by RECIST Criteria — 15 Participants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade During the First 4 Months of Treatment — 71.2; 80.8 percentage of participants — p=0.175
Head and Neck Cancer
Primary: Percentage of Participants With Local Regional Control — 91.1 percentage of subjects
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months
Advanced Malignant Neoplasm · Dermatologic Complication
Primary: Number of Patients Reporting a Grade 2+ Adverse Event Attributed to Spironolactone (Study I) — 0; 0 Participants
Head and Neck Cancer · Squamous Cell Carcinoma
Primary: Change in Tumor Size — 1; 3; 11 Participants
Colorectal Cancer
Primary: PFS Probability Rate at 9 Months in the Dose Escalation Arm — 45; 48; 0; 55 percent probability
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Erlotinib Associated Rash Stratified by Severity Grade at Week 2 — 11; 22; 0; 33 percentage of participants
Skin Toxicities
Primary: Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL) — 2.70; 2.41; 2.70; 2.29 units on a scale
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants
Squamous Cell Carcinoma of the Head and Neck
Primary: NK Cell Activation — 19; 20; 4; 3 percentage of activity
Colorectal Cancer
Primary: Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab. — 0; 9; 10 Participants
Colon Cancer · Rectum Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Develop Skin Rash — 60.0; 69.2; 73.1 percentage of participants — p=0.481
Dermatologic Complications · Malignant Neoplasm · Pain
Primary: Change From Baseline to Week 4 Face Pain Score Measuring Cutaneous Discomfort — 2.0; 3.0 score on a scale — p=0.6311
Lung Adenocarcinoma
Primary: The Maximum Tolerated Dose (MTD) of Cetuximab Given Every 2 Weeks — 500; 500; 500 mg/m2 of CETUXIMAB
Head and Neck Cancer · Precancerous Condition
Primary: Number of Participants With Objective Response Based on Histologic Grade — 13; 6 Participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Best Overall Response (BOR) — 68.2 percentage of participants
Head and Neck Cancer
Primary: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013 — 76; 68 participants
Anal Cancer
Primary: Local Failure Rate at 3 Years — 0.259; 0.353 proportion of participants — p=0.218
Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma
Primary: Progression — 1 Participants
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Pancreatic Cancer
Primary: Progression-free Survival at 6 Months — 82 percentage of participants